Category: Wall Street Beat
Medtronic is about 2/3 of the way through a restructuring plan involving 2,000 layoffs worldwide, with about half of the job cuts in the U.S., company officials say.
Medtronic (NYSE:MDT) is about ⅔ of the way through a restructuring program that includes layoffs for 2,000 workers worldwide, company officials said today, with about half of the job cuts coming in the U.S.
The hallowed emerging markets in Brazil, Russia, India and China aren't generating the kind of growth once expected for healthcare companies, according to a Frost & Sullivan report.
Emerging markets might not be all they're cracked up to be for healthcare companies, according to a Frost & Sullivan report, as protectionist import policies and competition from generics prove to be big challenges.
Markets the so-called BRIC countries – Brazil, Russia, India and China – aren't proving to be as easy to penetrate as healthcare companies once thought, according to F&S partner Reenita Das.
Shares of Johnson & Johnson are up 40% over the past year, but the rally hasn't accompanied strong, even financial performance, especially from its struggling medical device segment.
By Stephen Simpson
Weight-loss devices maker GI Dynamics tells investors today that the company may seek new funding as it works to support clinical trials in pursuit of U.S. regulatory approval.
Investors Down Under shied away from weight-loss devices maker GI Dynamics (ASX:GID) today after president & CEO Stuart Randle told shareholders that the company may need to raise new funds in order to support its clinical trials.
Covidien restates its financial results for its fiscal 2nd quarter ahead of the spinout of its Mallinckrodt pharmaceuticals business, expected next month.
Covidien (NYSE:COV) re-stated its financial results for the fiscal 3rd quarter ended March 29, in anticipation of the planned spinout of its Mallinckrodt pharmaceuticals business next month.
Covidien said the new numbers reflect the pharma unit as a discontinued operation, with COV shareholders slated to receive a tax-free distribution, according to a regulatory filing.
Natus Medical beats Wall Street's earnings forecast with a 1,000-fold profit surge on record sales, prompting the medical device company to raise its earnings forecast for the rest of the year.
Natus Medical (NSDQ:BABY) reported a 1,000% increase in profits during the 1st quarter, handily beating Wall Street's earnings-per-share forecast in the process.
Stryker (NYSE:SYK) CEO Kevin Lobo told an investors conference audience in Las Vegas yesterday that the medical device company is still in the mergers & acquisitions hunt, even after its newsmaking buyouts of China's Trauson Holdings, Israel's Orthovita and Surpass Medical.
